<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35787233</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.</ArticleTitle><Pagination><StartPage>1994</StartPage><EndPage>2006</EndPage><MedlinePgn>1994-2006</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2093132</ELocationID><Abstract><AbstractText>Coxsackievirus A16 (CVA16) is one of the major pathogens responsible for human hand, foot, and mouth disease (HFMD), which has threatened the health of young children, particularly in Asia-Pacific nations. Vaccination is an effective strategy for protecting children from CVA16 infection. However, there is currently no licensed CVA16 vaccine for use in humans. In this study, we isolated a high-growth CVA16 virus strain in MRC-5 cells and developed an MRC-5-adapted vaccine candidate strain termed CVA16-393 via two rounds of plaque purification. The CVA16-393 strain was grouped into the B1b subgenotype and grew to a titre of over 10<sup>7</sup> TCID<sub>50</sub>/ml in MRC-5 cells. The VP1 gene region of this strain, which contains the major neutralizing epitopes, displayed high stability during serial passages. The inactivated whole-virus vaccine produced by the CVA16-393 strain induced an effective neutralizing antibody response in <i>Meriones unguiculatus</i> (gerbils) after two doses of intraperitoneal inoculation. One week after the booster immunization, the geometric mean titres of the neutralizing antibodies for the 10246, 40812TXT, 11203SD, TJ-224 and CA16-194 strains from different regions of China were 137.8, 97.8, 113.4, 64.1 and 122.3, respectively. A CVA16 vaccine dose above 25 U was also able to provide 100% cross-protection against lethal challenges with these five clinical strains in gerbils. Immunization at a one-week interval could maintain a high level of neutralizing antibody titres for at least 8 weeks. Thus, the vaccine produced by this CVA16-393 strain might be promising.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yi-Sheng</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0002-6854-7630</Identifier><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Hang-Jing</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zi-An</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Zhejiang Pukang Biotechnology Co., LTD., Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Zhejiang Pukang Biotechnology Co., LTD., Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Tian-Yuan</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of General Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ping-Ping</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Han-Ping</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005849" MajorTopicYN="N">Gerbillinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">MRC-5 cell</Keyword><Keyword MajorTopicYN="N">gerbil</Keyword><Keyword MajorTopicYN="N">immunization</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35787233</ArticleId><ArticleId IdType="pmc">PMC9377242</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2093132</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han Z, Song Y, Xiao J, et al. . Genomic epidemiology of coxsackievirus A16 in mainland of China, 2000-18. Virus Evol. 2020 Jul;6(2):veaa084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733612</ArticleId><ArticleId IdType="pubmed">33343924</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, et al. . An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010 May;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. . Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Liu F, Liao Q, et al. . Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017 Dec;22(50):16–00824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, Pan H, Liu P, et al. . Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015 Mar;25(2):115–128.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Zeng H, Zheng H, et al. . Molecular surveillance of coxsackievirus A16 in southern China, 2008–2019. Arch Virol. 2021 Jun;166(6):1653–1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">33796884</ArticleId></ArticleIdList></Reference><Reference><Citation>He SJ, Han JF, Ding XX, et al. . Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in guangdong, 2010. Int J Infect Dis. 2013 Nov;17(11):e1025–e1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791223</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu CF, Yan L, et al. . Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 2012 Jan;9:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooi YT, Ong KC, Tan SH, et al. . Coxsackievirus A16 in a 1-Day-Old mouse model of central nervous system infection shows lower neurovirulence than enterovirus A71. J Comp Pathol. 2020;176:19–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32359633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Zhang H, Han Q, et al. . A vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages. Vaccine. 2015 Jan;33(2):374–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">25448099</ArticleId></ArticleIdList></Reference><Reference><Citation>Betáková T, Svetlíková D, Gocník M.. Overview of measles and mumps vaccine: origin, present, and future of vaccine production. Acta Virol. 2013;57(2):91–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">23600866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun YS, Li YJ, Xia Y, et al. . Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation. Sci Rep. 2016 Sep;6:34299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5035925</ArticleId><ArticleId IdType="pubmed">27667023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao PP, Miao ZP, Xu F, et al. . An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates. Vaccine. 2019 Aug;37(36):5341–5349.</Citation><ArticleIdList><ArticleId IdType="pubmed">31351798</ArticleId></ArticleIdList></Reference><Reference><Citation>vZhang Y, Wang D, Yan D, et al. . Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol. 2010 Feb;48(2):619–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815627</ArticleId><ArticleId IdType="pubmed">20018819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun YS, Xu F, An Q, et al. . A SARS-CoV-2 variant with the 12-bp deletion at E gene. Emerg Microbes Infect. 2020 Dec;9(1):2361–2367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598948</ArticleId><ArticleId IdType="pubmed">33118859</ArticleId></ArticleIdList></Reference><Reference><Citation>Arıkan SAN, Özbeyli D, Elmas MA, et al. . Effects of moderate aerobic exercise, low-level laser therapy, or their combination on muscles pathology, oxidative stress and irisin levels in the mdx mouse model of Duchenne muscular dystrophy. Lasers Med Sci. 2022 [cited 2022 April 19]: 1–12. doi:10.1007/s10103-022-03562-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10103-022-03562-8</ArticleId><ArticleId IdType="pubmed">35441320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping J, Lopes TJS, Nidom CA, et al. . Development of high-yield influenza A virus vaccine viruses. Nat Commun. 2015 Sep 2;6:8148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569720</ArticleId><ArticleId IdType="pubmed">26334134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Baz M, Lu J, et al. . Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol. 2014 Jun;88(12):7016–7023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054345</ArticleId><ArticleId IdType="pubmed">24719414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Liu Y, Zhang Y, et al. . Molecular phylogeny of coxsackievirus A16. J Clin Microbiol. 2014 Oct;52(10):3829–3830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4187763</ArticleId><ArticleId IdType="pubmed">25227616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, et al. . Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013 Apr;31(17):2130–2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Yang Y, Chi Y, et al. . Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for coxsackievirus A16 and enterovirus 71. Vaccine. 2015 Sep;33(39):5087–5094.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Liu Q, Ye X, et al. . A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014 Jul;32(34):4296–4303.</Citation><ArticleIdList><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Wu CN, Shih SR, et al. . Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine. 2002 Jun;20(19–20):2485–2493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec;383(27):2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Hou C, Li Y, et al. . mRNA vaccine: How to meet the challenge of SARS-CoV-2. Front Immunol. 2022;12:821538–821538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813741</ArticleId><ArticleId IdType="pubmed">35126377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Zhang KH, Na T, et al. . The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines. Sci Rep. 2017 Oct;7(1):12484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624879</ArticleId><ArticleId IdType="pubmed">28970485</ArticleId></ArticleIdList></Reference><Reference><Citation>An W Q, Su Z G, Pan R W, et al. . The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother. 2014;10(3):628–639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130287</ArticleId><ArticleId IdType="pubmed">24401488</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan S, Liao Y, Jiang G, et al. . Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. Vaccine. 2021 Jan;39(3):596–604.</Citation><ArticleIdList><ArticleId IdType="pubmed">33342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B, He LF, Zhang YL, et al. . Characteristics and viral propagation properties of a new human diploid cell line, Walvax-2, and its suitability as a candidate cell substrate for vaccine production. Hum Vaccin Immunother. 2015;11(4):998–1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526020</ArticleId><ArticleId IdType="pubmed">25803132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsugawa T, Tsutsumi H.. Genomic changes detected after serial passages in cell culture of virulent human G1P[8] rotaviruses. Infect Genet Evol. 2016 Nov;45:6–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">27543393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsugawa T, Tatsumi M, Tsutsumi H.. Virulence-associated genome mutations of murine rotavirus identified by alternating serial passages in mice and cell cultures. J Virol. 2014 May;88(10):5543–5558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019127</ArticleId><ArticleId IdType="pubmed">24599996</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, et al. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012 Nov;86(22):11967–11976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang Y, Zhang X, et al. . Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology. 2017 Jan;500:198–208.</Citation><ArticleIdList><ArticleId IdType="pubmed">27829175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Hong Q, Chen D, et al. . Permissibility of Mongolian gerbil for Angiostrongylus cantonensis infection and utility of this animal model for anthelmintic studies. Parasitol Res. 2014 May;113(5):1687–1693.</Citation><ArticleIdList><ArticleId IdType="pubmed">24556845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanafi HA, Fryauff DJ, Kittell CE.. Evaluation of the fat-tailed gerbil, Pachyuromys duprasi (Rodentia: Gerbillidae), as a new animal model for studies of Leishmania major infection and transmission. Vector Borne Zoonotic Dis. 2013 Sep;13(9):650–656.</Citation><ArticleIdList><ArticleId IdType="pubmed">23697770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>